(Adds details on drug price)
June 10 (Reuters) - The U.S. Food and Drug Administration granted accelerated approval to Roche Holding AG's combo lymphoma treatment for previously treated patients, the company said on Monday.
The drug, Polivy, is used in combination with Rituxan and a chemotherapy agent to treat an aggressive form of the disease.
Roche said the average U.S. list price for a four-month course of Polivy would be $90,000, and doses are determined after taking into consideration the weight of a patient.
Rituxan is priced at $39,500 for four months.
The combo was approved for adults, who have received at least two prior therapies for relapsed or refractory form of non-Hodgkin's lymphoma (NHL).
Roche estimates that nearly 25,000 new cases to be recorded in the United States this year.
NHL, which is one of the most common cancers, accounts for about 4% of all types of cancers in the United States, according to the American Cancer Society.
Continued approval for the treatment may depend on data from a confirmatory trial, Roche said.
The FDA's accelerated approval program allows conditional approval of a medicine that fills an unmet medical need for a serious condition. (Reporting by Aakash Jagadeesh Babu and Deena Beasley; Editing by Anil D'Silva and James Emmanuel)